George Nakayama Representative Director, Chairman and CEO Sunao Manabe Representative Director, Member of the Board, President and COO PLAY LIST fron the beginning Top Management Presentation Financial Results for FY2016 (April 1, 2016 - March 31, 2017) Forward-Looking Statements Agenda FY2016 Financial Results Overview of FY2016 Results Impairment loss: Kitasato Daiichi Sankyo Vaccine (KDSV) Revenue Operating Profit Special Items Profit Attributable to Owners of the Company Income Taxes, Non-Controlling Interests Revenue: Major Business Units Revenue: Major Products in Japan FY2017 Consolidated Forecast FY2017 Consolidated Forecast(1) FY2017 Consolidated Forecast(2) Revenue: Major Business Units Revenue: Global Products Progress of 5-Year Business Plan 2025 Vision 5-Year Business Plan (FY2016 - FY2020) Strategic Targets -For establishing foundation of sustainable growth- Grow Edoxaban Edoxaban Expand Launched and Approved Countries Growth in Japan(1) Growth in Japan(2) Growth in Germany and South Korea Maximize Product Value Accelerate New Evidence Creation(1) Accelerate New Evidence Creation(2) Grow as No.1 company in Japan Grow Major Products in Japan Process for Sustainable Growth Achievements in FY2016 Growth of Sales Share “Opioid Switching” is now Available in Japan Expand US Businesses Pain Franchise Luitpold Business The U.S. IV Iron Market New Sales Team for Injectafer Injectafer: Investigating Additional Indications Generic Injectable Franchise Establish Oncology Business Establish Oncology Business Established Biologics Unit (Apr 2017) Established Global Oncology Marketing (Apr 2017) ADC Franchise DS’s Proprietary ADC technology ADC technology: Mode of Action (MOA) ADC Franchise: DS pipeline Progress of ADC Franchise: DS-8201 HER2 ADC Progress of ADC Franchise: U3-1402 HER3 ADC(1) Progress of ADC Franchise: U3-1402 HER3 ADC(2) Progress of ADC Franchise: U3-1402 HER3 ADC(3) Other ADC Franchise: DS-1062 TROP2 ADC Other ADC Franchise: DS-7300 B7-H3 ADC AML Franchise AML Franchise: Developing 3 of 7 Emerging Classes of Targets Progress of AML Franchise: Quizartinib FLT3 inhibitor Continuously Generate Innovative Medicine Changing SOC (Standard of Care) Continuously Generate Innovative Medicine Changing SOC Oncology: Partnership for Changing SOC New Horizon Area: Partnership for Changing SOC Enhance Cash Flow Generation Capabilities Enhance Cash Flow Generation Capabilities: Streamlining of Assets(1) Enhance Cash Flow Generation Capabilities: Streamlining of Assets(2) Low Cost Funding & Efficient Operation for DS Group Cash Management Shareholder Returns Shareholder Returns Back-up FY2017 Major R&D Milestone Events Major R&D Pipeline @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Q&A 8 Back Next